Unpacking the Implications of the Negotiated Drug List, Part 1
Summary
Delve into the far-reaching implications of the recently announced negotiated drug list as Avalere experts provide insights and answers to pressing questions surrounding CMS's landmark decision on Part D drug pricing and its impact on manufacturers, patients, and the future healthcare landscape.
2024: Accelerate Impact
Sign up for our 2024 Healthcare Industry Outlook webinar
January 17, 1 PM ET
Learn More
Register Now
Learn More